The Roswell Park Lymphoma Translational Research Center
The investigators in the Hernandez-Ilizaliturri Lab are actively involved in clinical, translational and laboratory-based research projects to gain a better understanding of pathogenesis, prognostic factors, and cellular/molecular features associated with the development of “resistance” in these lymphoid neoplasms.
Lab Research
Overcoming acquired resistance to chemotherapy agents in aggressive B-cell lymphoma
Our research focuses on:
- Improving the biological activity of monoclonal antibodies or chimeric antigen receptor T-cell (CAR-T) therapy against b-cell lymphoma
- Overcoming rituximab-chemotherapy resistance in b-cell lymphoma
- Evaluating novel small molecule inhibitors targeting key-regulatory pathways in lymphomas
- Identifying of biomarkers of response to current available therapies in patients with B-cell lymphoma
- Evaluating the immunological effects of mRNA SaRS-COVD-19 vaccine in B-cell lymphoma patients
- Applying our pre-clinical work in the rational design of clinical trials for patients with lymphomas
"Our team continues to save lives and improve the quality of life of cancer patients in our community. It's a blessing and honor that often is hard to explain in words."
-Francisco Hernandez-Ilizaliturri, MD
Faculty affiliations
In the news
Contact Information
Connect with the Hernandez-Ilizaliturri Lab
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263